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Our results are in line with the findings
of Schmidt et al. (2009) who conclude
that apoptosis is not required for
pemphigus acantholysis. Like us, they
found no evidence of positive cl caspase
3 and TUNEL when analyzing lesional PV
patient skin. Moreover, in cultures of
human keratinocytes treated with PV
IgG, they also found acantholysis in
absence of positive TUNEL staining as
well as caspase 3 cleavage. Lee et al.
(2009) also disagreed that apoptosis is an
upstream event in pemphigus acantho-
lysis. In PF IgG–treated mice and PV
IgG–treated keratinocyte cultures, they
found activation of cl PARP, cl caspase
3, and TUNEL, but only after acantholysis.
The belief that apoptosis is an
upstream event in acantholysis is largely
based on studies in model systems
(Schmidt and Waschke, 2009). We
question whether these model systems
are suitable for answering such
questions on pemphigus pathogenesis,
as they differ from the in vivo situation.
For instance, in cultured keratinocytes
the desmosomal makeup in terms of
molecular composition does not
accurately reflect the in vivo situation
(van der Wier et al., 2010). As for mouse
models, the repertoire of expressed
genes involved in apoptosis in humans
and mice is different (Reed et al., 2003).
Furthermore, previous data on pem-
phigus skin are scarce and based on a
few lesional biopsies only (Wang et al.,
2004; Pacheco-Tovar et al., 2009,
Deyhimi and Tavakoli, 2012).
In conclusion, this study does not
support the hypothesis that apoptosis is
involved in pemphigus acantholysis.
However, although we studied morpho-
logical hallmarks of apoptosis, the invol-
vement of certain apoptotic caspases or
signaling pathways, which might be
involved in dissociation of (inter)desmo-
somal adhesion complexes, cannot be
excluded (Grando et al., 2009).
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TO THE EDITOR
A keloid is a fibroproliferative disorder
of the skin (Tredget, 1994) that is caused
by pathological wound-healing pro-
cesses (Gurtner et al., 2008). The
development and progression of
keloids relate closely to genetic factors
(Marneros et al., 2004; Nakashima
et al., 2010), systemic factors such as
hypertension (Arima et al., 2012) and
pregnancy (Park and Chang 2012), and
the local microenvironment (e.g., skin
stretching force/tension, (Ogawa et al.,
2012a)). A genome-wide associationAccepted article preview online 4 February 2014; published online 27 February 2014
Abbreviations: CI, confidence interval; GWAS, genome-wide association study; NEDD4, neuronal
precursor cell-expressed developmentally downregulated 4; SNP, single-nucleotide polymorphism
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study (GWAS) identified four single-
nucleotide polymorphisms (SNPs)
in Japanese patients with keloids
(Nakashima et al., 2010), namely,
rs873549, rs1511412, rs940187, and
rs8032158 in three chromosomal
regions (1q41, 3q22.3-23, and 15q21.3).
However, whether these SNPs asso-
ciate with keloid severity has not yet
been studied. Thus, in the present study,
the relationships between keloid severity
and these four SNPs were assessed in
204 Japanese patients. In this study,
SNPs were found to associate with the
clinical severity of keloids. This pros-
pective study was approved by the
ethics committee of Nippon Medical
School. The tenets of the Declaration
of Helsinki were followed and written
informed consent was given by the
patients.
Comparison of the patients with
keloids and the HapMap Japanese con-
trols (Tokyo, Japan) revealed that the
patients differed from the controls in
terms of rs873549 and rs8032158 allele
frequencies. Differences between the
cases and controls in terms of genotype
frequency were tested by using the chi-
squared test and by calculating odds
ratios (ORs) and 95% confidence inter-
vals (CIs) (Table 1). With regard to
rs873549, the ORs were large, especially
in the recessive mode of inheritance,
where the odds of the homozygous risk
allele (C/C) were compared with the
odds of T/TþC/T (OR: 4.8, 95% CI:
1.94–14.19; P-value by Fisher’s exact
probability test 1.81104). This result
suggested that there is a significant
relationship between inherited pattern
C/C and keloid susceptibility. The
rs8032158 SNP also had large ORs,
especially in the dominant mode of inheri-
tance, where the odds of C/TþC/C
(containing the risk allele) were com-
pared with the odds of T/T (without
the risk allele) (OR: 3.02, 95%
CI: 1.71–5.31; P-value 3.19 10 5).
These differences were maintained after
Bonferroni’s correction. The results with
rs873549 and rs8032158 are consistent
with those of the previously described
GWAS study. However, the rs1511412
and rs940187 SNPs did not associate
significantly with keloid susceptibility.
In this study, the power of the
rs1511412 and rs940187 analyses was
poor, whereas that of the rs873549
and rs8032158 was much higher
(Table 1). This may explain why only
rs873549 and rs8032158 associated
strongly with keloid susceptibility in
our study.
The 204 cases were then divided
according to keloid severity (severe vs.
mild) or keloid number (multiple vs.
single) (see Supplementary Informa-
tion online). Keloid severity was classi-
fied on the basis of the Japan Scar
Workshop Scar Scale (Ogawa et al.,
2012b) as mild (0–15 points) or severe
(16–25 points). Assessment of rs8032158
revealed that in the dominant mode of
inheritance (where C/TþC/C is
compared with T/T), the severe keloid
group had significant ORs compared
with both the controls (see Table 2) and
the mild keloid group (Table 2). The ORs
were maintained after Bonferroni’s cor-
rection (OR: 4.73, 95% CI: 2.38–9.48,
P-value 8.3410 7, respectively). The
ratio of the severe:mild OR for
rs8032158 (dominant model) leads
directly to that presented in Table 2
(i.e. 4.73/1.84¼2.57) (Supplementary
Information online). Thus, rs8032158
associated strongly with severe keloids.
Similar associations were not seen for
mild, single, or multiple keloids com-
pared with the control group. Associa-
tions between keloid number or severity
relative to the controls were not
observed for the other three SNPs (see
Table 2 and Supplementary Information
online). However, different relationships
may emerge if ‘severe keloid occurrence’
is defined as the presence of more than
three keloids.
The rs8032158 SNP is located
in intron 5 of the neuronal precursor
cell-expressed developmentally down-
regulated 4 (NEDD4) gene on chromo-
some 15 (Nakashima et al., 2010).
NEDD4 expresses an E3 ubiquitin
ligase with a HECT domain that is
involved in ubiquitin-mediated protein
degradation (Chung et al., 2011).
NEDD4 activation is reported to
affect the subcellular localization and
protein stability of p27, which suggests
that it has a critical role in contact
inhibition. It also induces the accumu-
lation of b-catenin in the cytoplasm and
activates TGFb-catenin transcriptional
activity. Furthermore, NEDD4 acti-
vation upregulates the expression of
fibronectin and type 1 collagen
and may thereby contribute to the
excessive accumulation of extracellular
matrix. Thus, the rs8032158 SNP
may have a role in the aberrant cell
proliferation and matrix accumu-
lation seen in keloids, although further
studies are needed to test this
notion.
Table 1. Association between single-nucleotide polymorphisms and keloid
susceptibility in the Japanese population keloid patients (all) versus HapMap
controls
SNP Allele (risk) Mode Odds ratio (95% CI) P-value Power
rs873549 T/C (C) Dominant 2.09 (1.19–3.65) 5.42 10 3 0.79
Recessive 4.8 (1.942–14.19) 1.82 10 4 0.99
Allele 2.14 (1.45–3.19) 6.00 10 5 0.98
rs1511412 G/A (A) Dominant 1.01 (0.53–2.00) 9.77 10 1 0.05
Recessive Inf (0.61–Inf) 8.20 10 2 NaN
Allele 1.20 (0.66–2.25) 5.41 10 1 0.09
rs940187 C/T (T) Dominant 0.85 (0.42–1.8) 6.33 10 1 0.08
Recessive Inf (0.50–Inf) 1.08 10 1 NaN
Allele 1.04 (0.54–2.11) 8.94 10 1 0.05
rs8032158 T/C (C) Dominant 3.020 (1.71–5.31) 3.19 10 5 0.98
Recessive 2.09 (1.06–4.33) 2.35 10 2 0.63
Allele 2.17 (1.47–3.21) 3.65 10 5 0.99
Abbreviations: CI, confidence interval; Inf, infinity; NaN, not a number; SNP, single-nucleotide
polymorphism.
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As keloid scars may be the result
of abnormal and pathological wound
healing, it is important to manage the
wound carefully, especially in patients
who are genetically predisposed to
keloid development. For example,
if a genetic analysis shows that a patient
bears genetic markers of susceptibility to
severe keloids, certain actions can
be taken to prevent the development
of keloids after surgery. These
actions include administering adjuvant
therapies (Ogawa, 2010) such as
corticosteroids or radiation therapy
immediately after surgery.
In summary, although systemic and
local factors may promote keloid sever-
ity, our study shows that genetic factors,
specifically the rs8032158 SNP, may
also influence keloid severity. To the
best of our knowledge, it is previously
unreported that an association between
SNPs and keloid clinical severity has
been detected. This SNP may be a
biomarker for the prevention of keloids
in clinical situations.
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SNP Allele (risk) Mode Odds ratio (95% CI) P-value Power
1) Mild keloids vs. HapMap
rs873549 T/C (C) Dominant 2.01 (1.02–4.00) 3.01 10 2 0.58
Recessive 4.66 (1.66–14.777) 8.37 10 4 0.92
Allele 2.09 (1.31–3.32) 1.01 10 3 0.91
rs1511412 G/A (A) Dominant 1.02 (0.46–2.27) 9.69 10 1 0.05
Recessive Inf (0.19–Inf) 1.53 10 1 NaN
Allele 1.14 (0.55–2.29) 7.02 10 1 0.07
rs940187 C/T (T) Dominant 1.01 (0.43–2.41) 9.72 10 1 0.05
Recessive Inf (0.42–Inf) 7.88 10 2 NaN
Allele 1.24 (0.57–2.75) 5.59 10 1 0.09
rs8032158 T/C (C) Dominant 1.84 (0.95–3.58) 5.08 10 2 0.50
Recessive 1.38 (0.60–3.25) 4.12 10 1 0.13
Allele 1.52 (0.96–2.41) 6.25 10 2 0.46
2) Severe keloids vs. HapMap
rs873549 T/C (C) Dominant 2.15 (1.15–4.04) 9.97 10 3 0.73
Recessive 4.90 (1.88–15.01) 2.94 10 4 0.97
Allele 2.19 (1.449–3.187) 1.67 10 4 0.97
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Recessive Inf (0.30–Inf) 1.38 10 1 NaN
Allele 0.91 (0.42–1.99) 7.89 10 1 0.06
rs8032158 T/C (C) Dominant 4.73 (2.38–9.48) 8.34 10 7 0.99
Recessive 2.70 (1.30–5.81) 3.75 10 3 0.84
Allele 2.81 (1.83–4.32) 5.18 10 7 0.99
Abbreviations: CI, confidence interval; Inf, infinity; NaN, not a number; SNP, single-nucleotide
polymorphism.
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